IMNEWRUN Overview

  • Year Founded
  • 2019

Year Founded

  • Status
  • Private

  • Employees
  • 38

Employees

  • Latest Deal Type
  • Later Stage VC

  • Investors
  • 11

IMNEWRUN General Information

Description

Developer of precision-engineered antibody-based brain delivery therapeutics designed to address neurological disorders. The company's platform leverages structural biology, artificial intelligence, and cryo-electron microscopy to engineer antibodies capable of crossing the blood-brain barrier with high selectivity, integrating drug development capabilities within an enterprise-academia research infrastructure, enabling neuroscience researchers and healthcare stakeholders to advance treatment of complex brain diseases with greater precision and scientific rigor.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5th Floor, North Center Building A
  • 2066, Seobu-ro, Jangan-gu
  • Suwon, Gyeonggi 16419
  • South Korea
+82
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • 5th Floor, North Center Building A
  • 2066, Seobu-ro, Jangan-gu
  • Suwon, Gyeonggi 16419
  • South Korea
+82

IMNEWRUN Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

IMNEWRUN Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 13-May-2026 Completed Pre-Clinical Trials
7. Grant 22-Aug-2024 Completed Pre-Clinical Trials
6. Accelerator/Incubator Completed Pre-Clinical Trials
5. Accelerator/Incubator 31-May-2024 Completed Pre-Clinical Trials
4. Grant 01-Apr-2024 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 28-May-2021 Completed Pre-Clinical Trials
2. Seed Round 28-Sep-2020 $8.53M $17.1M Completed Pre-Clinical Trials
1. Seed Round 03-Jul-2019 $8.54M $8.54M Completed Pre-Clinical Trials
To view IMNEWRUN’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

IMNEWRUN Patents

IMNEWRUN Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024091079-A1 Blood-brain barrier permeable fusion protein and uses thereof Inactive 28-Oct-2022
WO-2024080843-A1 Blood-brain barrier permeable fusion protein and use thereof Inactive 14-Oct-2022
AU-2022428997-A1 Blood-brain barrier permeable fusion protein and uses thereof Active 31-Dec-2021
AU-2022428997-B2 Blood-brain barrier permeable fusion protein and uses thereof Active 31-Dec-2021
EP-4458848-A1 Blood-brain barrier permeable fusion protein and uses thereof Pending 31-Dec-2021 C07K14/70582
To view IMNEWRUN’s complete patent history, request access »

IMNEWRUN Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

IMNEWRUN Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hyosung Ventures Corporate Venture Capital Minority
Endless Frontier Labs Accelerator/Incubator
Korea Dementia Research Center (KDRC) Corporation Minority
GTO Investment Venture Capital Minority
InterVest Venture Capital Minority
You’re viewing 5 of 11 investors. Get the full list »

IMNEWRUN FAQs

  • When was IMNEWRUN founded?

    IMNEWRUN was founded in 2019.

  • Where is IMNEWRUN headquartered?

    IMNEWRUN is headquartered in Suwon, South Korea.

  • What is the size of IMNEWRUN?

    IMNEWRUN has 38 total employees.

  • What industry is IMNEWRUN in?

    IMNEWRUN’s primary industry is Biotechnology.

  • Is IMNEWRUN a private or public company?

    IMNEWRUN is a Private company.

  • What is IMNEWRUN’s current revenue?

    The current revenue for IMNEWRUN is .

  • How much funding has IMNEWRUN raised over time?

    IMNEWRUN has raised $43.8M.

  • Who are IMNEWRUN’s investors?

    Hyosung Ventures, Endless Frontier Labs, Korea Dementia Research Center (KDRC), GTO Investment, and InterVest are 5 of 11 investors who have invested in IMNEWRUN.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process